Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

NG-641

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Akamis Bio

Drug class:

CD3 agonist, IFNα stimulant, FAP inhibitor, CXCL10 stimulant, CXCL9 stimulant

Related drugs:

177Lu-DOTA-EB-FAPI (0)

177Lu-LNC1004 (0)

[177Lu]FAPI-46 (0)

blinatumomab (52)

epcoritamab-bysp (11)

elranatamab-bcmm (8)

tebentafusp-tebn (7)

tarlatamab-dlle (4)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

odronextamab (1)

JNJ-63898081 (1)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

linvoseltamab (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

ABBV-383 IV (0)

huCD33-BsAb (0)

pegylated interferon α -2a (3)

nadofaragene firadenovec-vncg (1)

interferon alfa 2b (0)

recombinant interferon alfa-2a (0)

Autologous CD34+ enriched HSPCs expressing interferon-alpha 2 (0)

peginterferon-α-2b (0)

177Lu-DOTA-EB-FAPI (0)

177Lu-LNC1004 (0)

[177Lu]FAPI-46 (0)

›